Sciampa is indicated
as an adjunct to diet and exercise to improve glycemic control
in adults with type 2 diabetes mellitus as;
When diet and
exercise alone do not provide adequate glycemic control in
patients for whom use of metformin is considered inappropriate
due to intolerance.
with other glucose-lowering medicinal products including insulin,
when these, together with diet and exercise, do not provide
adequate glycemic control.
Empagliflozin is a sodium-glucose co-transporter
2 (SGLT2) inhibitor. It lowers blood sugar by causing the
kidneys to get rid of more glucose in the urine. Empagliflozin
is used with a proper diet and exercise program to control
high blood sugar in people with type 2 diabetes. Controlling
high blood sugar helps prevent kidney damage, blindness, nerve
problems, loss of limbs, and sexual function problems. Empagliflozin
is also used in patients with type 2 diabetes and heart disease
to lower the risk of death from heart attack or stroke.